The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has published a positive opinion for omaweloxolone, the first therapeutic solution to treat Friedreich's ataxia, a rare neurodegenerative disease.
- Friedreich's ataxia is a genetic, debilitating and life-shortening neuromuscular disease
- Biogen is expanding its drug portfolio for rare neuromuscular diseases for patients who have so far been left without any treatment.
Friedreich's Ataxia (FA) is a rare genetic neuromuscular disease that shortens life and devastates the patient's body. It is the most common form of hereditary ataxia. Early symptoms of FA, such as progressive loss of coordination, muscle weakness and fatigue, usually appear in childhood and may initially suggest other diseases. Most people with FA will need to start using a wheelchair within 10-20 years of the first symptoms. The average ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
